UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K/A

(Amendment no. 1)

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

January 29, 2016

Date of Report (Date of earliest event reported)

 

ELITE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware  001-15697  22-3542636
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

165 Ludlow Avenue, Northvale, New Jersey 07647

(Address of principal executive offices)

 

(201) 750-2646

(Registrant’s telephone number, including area code)

  

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Explanatory Note

 

This Current Report on Form 8-K/A amends the Current Report on Form 8-K filed by Elite Pharmaceuticals, Inc. (the "Company") on February 4, 2016 (the “Original 8-K”) solely to file the letter from Demetrius Berkower LLC (“Demetrius”), which firm was dismissed as the Company’s independent registered public accounting firm, addressed to the Securities and Exchange Commission stating whether Demetrius agrees with certain statements made in the Original 8-K.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

16.1Letter dated February 5, 2016, from Demetrius Berkower LLC. to the Securities and Exchange Commission.

 

 

 

 

SIGNATURE

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: February 5, 2016

 

  ELITE PHARMACEUTICALS, INC.  
       
       
  By: /s/ Nasrat Hakim  
  Name: Nasrat Hakim  
  Title: President & Chief Executive Officer